Our Purpose
Metabolic dysfunction–associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is increasingly recognized as one of the most common causes of liver disease worldwide. To better understand the global impact of this liver disease, the Global NASH/MASH Council (GNC) was established in 2014, bringing together renowned experts from across regions to collaborate and exchange insights on NASH/MASH. Today, the Global NASH Council includes 326 members from 65 countries spanning all continents. Council members engage in collaborative initiatives aimed at improving understanding of the global burden of NASH/MASH. The GNC has been endorsed by multiple organizations; for additional information, please refer to our Mission, Vision and Values. Serving as a global think tank, the GNC works to generate and disseminate evidence and inform policy related to MASLD and MASH in every region of the world.
About UsThe Global NASH/MASH
Council™ (GNC)
The Global NASH/MASH Council (GNC) was established in 2014 as a global think tank to unite international experts in discussing, collaborating, and advancing the field of MASH/NASH. Given the worldwide prevalence of MASLD/MASH, incorporating perspectives from diverse regions is essential to accurately assess the epidemiologic, clinical, and economic impact of this important liver disease within the context of each country and region. The GNC has undertaken more than 40 international collaborative projects and publishes approximately two dozen manuscripts annually, along with numerous abstracts submitted to major international scientific meetings. The Council meets in person each year at AASLD and EASL, and periodically at APASL, ALEH, and other key gatherings such as INASL, COLDA, and SASLT. These in-person meetings provide updates on GNC activities, facilitate discussion of emerging topics, and support the development of joint projects that advance understanding of this disease. Many members of the Council also serve as active participating sites for the Global NASH Registry™.
Learn More
The Global MASH and Liver Registries
Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide. Although the etiology and contributing factors vary across geographic regions, nonalcoholic steatohepatitis/metabolic dysfunction–associated steatohepatitis (NASH/MASH) has emerged as one of the most prevalent causes of CLD globally. In addition, alcohol-associated liver disease (ALD), viral hepatitis, and cholestatic liver diseases continue to affect thousands of individuals each day. The burden of these conditions extends beyond clinical complications, profoundly influencing patients’ health-related quality of life and other patient-reported outcomes (PROs). To better characterize the global burden of these liver diseases, our international registries were established to enroll individuals with NAFLD/MASLD, hepatitis B, C, and D, ALD, and primary biliary cholangitis (PBC) from diverse regions around the world. Within these registries, clinical information, laboratory data, and validated PRO measures are collected for each participant following approval by the relevant institutional ethics committees. All data are de-identified and entered into a secure, password-protected centralized platform. Participants are subsequently followed at each site on an annual basis.
Learn More